文献速递乳腺癌

全乳或部分乳腺放疗后5年患者报告结局:IMPORT LOW(CRUK/06/003)III期随机对照试验纵向分析

Patient-Reported Outcomes Over 5 Years After Whole- or Partial-Breast Radiotherapy: Longitudinal Analysis of the IMPORT LOW (CRUK/06/003) Phase III Randomized Controlled Trial.
PubMed 文献 · J Clin Oncol · 2018-12-11

IMPORT LOW研究纳入低危乳腺癌保乳术后患者,随机分为40 Gy全乳放疗(对照)、36 Gy全乳联合40 Gy部分乳腺放疗(减剂量)、40 Gy单纯部分乳腺放疗(部分乳腺)三组,均15次分割。报告5年患者报告结局:多数不良效应随时间减少,部分乳腺组与减剂量组平均不良事件数少于全乳组;并识别了不良事件报告的基线预测因素。

要点

  • 部分乳腺组与减剂量组平均不良事件数低于全乳组,且各组均随时间下降
  • 乳房外观改变最常见且持续存在,各时间点约20%
  • 年轻、乳房较大/手术缺损较大、淋巴结阳性、焦虑抑郁水平较高为后续不良事件报告的基线预测因素

核心结论

  • 大多数不良效应随时间减少,部分乳腺组与减剂量组的不良事件较少;研究识别了不良事件报告的基线预测因素,这些发现将有助于未来接受中度大分割乳腺放疗患者的知情讨论与共同决策。

研究设计与样本

  • IMPORT LOW为III期随机对照试验,招募保乳术后低危乳腺癌女性,随机分为40 Gy全乳放疗(对照)、36 Gy全乳联合40 Gy部分乳腺放疗(减剂量)、40 Gy单纯部分乳腺放疗(部分乳腺),均15次分割。
  • 患者报告结局子研究纳入71个中心中的41个中心,1,333例患者中1,265例(95%)知情同意。
  • 使用欧洲癌症研究与治疗组织生活质量问卷核心30、乳腺癌特异性模块、体像量表、方案特异性条目及医院焦虑抑郁量表,在基线、6个月及1、2、5年时施测。

主要发现

  • 962例中557例(58%)在5年时报告无中度/明显不良事件。
  • 乳房外观改变最常见并持续存在,各时间点约20%。
  • 乳房硬度、疼痛、过度敏感、水肿和皮肤改变的患病率随时间下降(每项P<.001),而乳房缩小随时间增加(P<.001)。
  • 按治疗组分析,人均平均不良事件数部分乳腺组低于全乳组(发生率比0.77;95%CI 0.71至0.84;P<.001),减剂量组低于全乳组(发生率比0.83;95%CI 0.76至0.90;P<.001),且所有组均随时间下降。
  • 较年轻年龄、较大乳房尺寸/手术缺损、淋巴结阳性及较高焦虑/抑郁水平是后续不良事件报告的基线预测因素。

关键数值与推荐

  • 部分乳腺组 vs 全乳组:人均平均不良事件数发生率比0.77(95%CI 0.71至0.84;P<.001)。
  • 减剂量组 vs 全乳组:人均平均不良事件数发生率比0.83(95%CI 0.76至0.90;P<.001)。
  • 乳房硬度、疼痛、过度敏感、水肿和皮肤改变患病率随时间下降,每项P<.001;乳房缩小随时间增加,P<.001。
  • 5年时962例中557例(58%)报告无中度/明显不良事件;乳房外观改变各时间点约20%。

临床怎么用

  • 作者认为这些发现将有助于未来接受中度大分割乳腺放疗患者的知情讨论与共同决策。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: IMPORT LOW demonstrated noninferiority of partial-breast and reduced-dose radiotherapy versus whole-breast radiotherapy for local relapse and similar or reduced toxicity at 5 years. Comprehensive patient-reported outcome measures collected at serial time points are now reported. PATIENTS AND METHODS: IMPORT LOW recruited women with low-risk breast cancer after breast-conserving surgery. Patients were randomly assigned to 40 Gy whole-breast radiotherapy (control), 36 Gy whole-breast and 40 Gy partial-breast radiotherapy (reduced-dose), or 40 Gy partial-breast radiotherapy only (partial-breast) in 15 fractions. European Organisation for Research and Treatment of Cancer Quality of Life Questionnaires Core 30 and Breast Cancer-Specific Module, Body Image Scale, protocol-specific items, and the Hospital Anxiety and Depression Scale were administered at baseline, 6 months, and 1, 2, and 5 years. Patterns of moderate/marked adverse effects (AEs) were assessed using longitudinal regression models, and baseline predictors were investigated. RESULTS: A total of 41 of 71 centers participated in the patient-reported outcome measures substudy; 1,265 (95%) of 1,333 patients consented, and 557 (58%) of 962 reported no moderate/marked AEs at 5 years. Breast appearance change was most prevalent and persisted over time (approximately 20% at each time point). Prevalence of breast hardness, pain, oversensitivity, edema, and skin changes reduced over time ( P < .001 for each), whereas breast shrinkage increased ( P < .001). Analysis by treatment group showed average number of AEs per person was lower in partial-breast (incidence rate ratio, 0.77; 95% CI, 0.71 to 0.84; P < .001) and reduced-dose (incidence rate ratio, 0.83; 95% CI, 0.76 to 0.90; P < .001) versus whole-breast group and decreased over time in all groups. Younger age, larger breast size/surgical deficit, lymph node positivity, and higher levels of anxiety/depression were baseline predictors of subsequent AE reporting. CONCLUSION: Most AEs reduced over time, with fewer AEs in the partial-breast and reduced-dose groups. Baseline predictors for AE reporting were identified. These findings will facilitate informed discussion and shared decision making for future patients receiving moderately hypofractionated breast radiotherapy.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Bhattacharya IS, Haviland JS, Kirby AM, et al. Patient-Reported Outcomes Over 5 Years After Whole- or Partial-Breast Radiotherapy: Longitudinal Analysis of the IMPORT LOW (CRUK/06/003) Phase III Randomized Controlled Trial. J Clin Oncol. 2018. PMID: 30532984. doi:10.1200/JCO.18.00982

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。